{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:07:15Z","timestamp":1777493235230,"version":"3.51.4"},"reference-count":0,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2009,6]]},"abstract":"\n Objective:<\/jats:title>\n The aim of this study was to determine the effectiveness and tolerability of aripiprazole for irritability in pervasive developmental disorder not otherwise specified (PDD-NOS) and Asperger's disorder.<\/jats:p>\n <\/jats:sec>\n \n Method:<\/jats:title>\n This is a 14-week, prospective, open-label investigation of aripiprazole in 25 children and adolescents diagnosed with PDD-NOS or Asperger's disorder. Primary outcome measures included the Clinical Global Impressions\u2013Improvement (CGI-I) scale and the Irritability subscale of the Aberrant Behavior Checklist (ABC-I).<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Twenty-five subjects, ages 5\u201317 years (mean 8.6 years) received a mean final aripiprazole dosage of 7.8\u2009mg\/day (range 2.5\u201315\u2009mg\/day). Full-scale intelligence quotient (IQ) scores ranged from 48 to 122 (mean 84). Twenty-two (88%) of 25 subjects were responders in regard to interfering symptoms of irritability, including aggression, self-injury, and tantrums, with a final CGI-I of 1 or 2 (very much or much improved) and a 25% or greater improvement on the ABC-I. The final mean CGI-I was 1.6 (\n p<\/jats:italic>\n \u2009\u2264\u20090.0001). ABC-I scores ranged from 18 to 43 (mean 29) at baseline, whereas scores at week 14 ranged from 0 to 27 (mean 8.1) (\n p<\/jats:italic>\n \u2009\u2264\u20090.001). Aripiprazole was well tolerated. Mild extrapyramidal symptoms (EPS) were reported in 9 subjects. Age- and sex-normed body mass index (BMI) increased from a mean value of 20.3 at baseline to 21.1 at end point (\n p<\/jats:italic>\n \u2009\u2264\u20090.04). Prolactin significantly decreased from a mean value of 9.3 at baseline to 2.9 at end point (\n p<\/jats:italic>\n \u2009\u2264\u20090.0001). No subject exited the study due to a drug-related adverse event.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n These preliminary data suggest that aripiprazole may be effective and well tolerated for severe irritability in pediatric patients with PDD-NOS or Asperger's disorder. Larger-scale placebo-controlled studies are needed to elucidate the efficacy and tolerability of aripiprazole in this understudied population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1089\/cap.2008.093","type":"journal-article","created":{"date-parts":[[2009,6,11]],"date-time":"2009-06-11T15:59:42Z","timestamp":1244735982000},"page":"265-274","source":"Crossref","is-referenced-by-count":80,"title":["Aripiprazole in Pervasive Developmental Disorder Not Otherwise Specified and Asperger's Disorder: A 14-Week, Prospective, Open-Label Study"],"prefix":"10.1177","volume":"19","author":[{"given":"Kimberly A.","family":"Stigler","sequence":"first","affiliation":[{"name":"Indiana University School of Medicine and Christian Sarkine Autism Treatment Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan T.","family":"Diener","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine and Christian Sarkine Autism Treatment Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arlene E.","family":"Kohn","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine and Christian Sarkine Autism Treatment Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Li","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig A.","family":"Erickson","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine and Christian Sarkine Autism Treatment Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Posey","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine and Christian Sarkine Autism Treatment Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"McDougle","sequence":"additional","affiliation":[{"name":"Indiana University School of Medicine and Christian Sarkine Autism Treatment Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,6,1]]},"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2008.093","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2008.093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:54:32Z","timestamp":1777388072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2008.093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1089\/cap.2008.093"],"URL":"https:\/\/doi.org\/10.1089\/cap.2008.093","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}